CCL19 and familial pancreatic carcinoma: The same team validated the use of anti-mesothelin IL-7/CCL19-producing human CAR-T cells in a preclinical model of orthotopic pre-established malignant mesothelioma, as well as in patient derived xenograft (PTX) models of mesothelin-positive pancreatic cancer.